Hardiman Roy C. sold $71K of ALMS

Hardiman Roy C. (Chief Business & Strategy Ofcr) sold 2,692 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Hardiman Roy C.
Published Aug 5, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings) by an officer, with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may note insider selling as a minor sentiment datapoint, but there is no accompanying company-specific catalyst.

03

What to watch

The filing does not disclose intent, tax context, or whether other insiders are trading; without follow-on buys/sales patterns, signal quality is low.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS insider Form 4 shows officer Hardiman Roy C. sold 2,692 shares for about $70,988 at $26.37 on 2026-08-03.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing lacks context on motives, and the transaction size is modest relative to typical market moves.

Market effects

No clear sector read-through from a single insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan does not necessarily imply negative information; insiders may sell for diversification, taxes, or planned liquidity needs.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed on Form 4.

  • Hardiman Roy C.

    Chief Business & Strategy Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.